免疫治疗对重症肺炎患者免疫功能指标及TNF―αIL―6水平影响研究.docVIP

免疫治疗对重症肺炎患者免疫功能指标及TNF―αIL―6水平影响研究 　　【摘要】 目的：研究免疫治??对重症肺炎患者免疫功能指标及TNF-α、IL-6水平的影响。方法：以本院2012年8月-2016年7月收治的120例重症肺炎患者作为研究对象，随机分为对照组和治疗组，各60例。对照组进行常规治疗，治疗组则在常规治疗的基础上加用胸腺肽α1免疫治疗1周，比较两组患者治疗后的免疫功能指标、TNF-α、IL-6水平。结果：治疗1周后，治疗组患者的单核细胞人白细胞抗原-DR（mHLA-DR）表达率上升，TNF-α和IL-6的表达含量均显著降低，CD4+含量和CD4+/CD8+比值均显著上升，CD8+含量降低，与对照组比较，差异均有统计学意义（P0.05）。治疗组肺部感染控制窗出现时间为（8.3±2.7）d，对照组肺部感染控制窗出现时间为（11.4±2.8）d。治疗组总有效率高于对照组，死亡率低于对照组，差异均有统计学意义（P0.05）。结论：胸腺肽α1免疫治疗可以有效提高重症肺炎患者的细胞免疫功能，有效降低全身炎症反应，显著提高临床疗效，有效改善患者预后，胸腺肽α1免疫治疗1周后mHLA-DR表达率显著上升，mHLA-DR、TNF-α和IL-6可以有效用于预测免疫治疗效果。 　　【关键词】 重症肺炎； 免疫治疗； CD4+； CD8+； 单核细胞人白细胞抗原-DR 　　The Effect of Immunotherapy on Immune Function and TNF-α，IL-6 in Patients with Severe Pneumonia/LYU Li-yan.//Medical Innovation of China，2017，14（12）：016-019 　　【Abstract】 Objective：To study the effect of immunotherapy on immune function and TNF-α，IL-6 in patients with severe pneumonia.Method：120 patients with severe pneumonia in our hospital from August 2012 to July 2016 were selected as the research objects，they were randomly divided into treatment group and control group，60 cases in each group.The control group was given routine treatment，on the basis of routine treatment，the treatment group was treated with thymosin α1 for 1 week，the immune function and serum TNF-α，IL-6 of two groups after treatment were compared.Result：After 1 week of treatment，the expression rate of mHLA-DR in the treatment group was increased，the expression of TNF-α and IL-6 were significantly decreased，the CD4+ content and CD4+/CD8+ ratio were significantly increased，and the content of CD8+ decreased，compared with the control group，the differences were statistically significant（P0.05）.The pulmonary infection control window in treatment group was（8.3±2.7）days and the control group was（11.4±2.8）days.The total effective rate of treatment group was higher than that of control group，the mortality rate of treatment group was lower than that of control group，the differences were statistically significant（P0.05）.Conclu